AMO PHARMA

New medicines. Better lives.

A Unique Drug Development Model

AMO Pharma is identifying and advancing promising therapies based on a unique business model designed to achieve new levels of innovation and efficiency. Our approach is based on many core strengths:

- A comprehensive understanding of disease mechanism of action and impact on patient health and quality of life.
- A global network of contacts in research and drug development to identify de-risked therapies that present promising opportunities for clinical development.
- Insights to complete a comprehensive review of safety and efficacy data for each asset.
- Identification of clear protocols and opportunities to "jump start" and streamline clinical development programs.
- Flexibility to consider acquisition of assets to address unmet needs in a range of therapeutic areas and in smaller and larger patient populations.
- Established relationships with third parties related to advancing research, commercialization strategies, and partnering and licensing opportunities.

AMO Pharma, Ltd., is a privately held emerging biopharmaceutical company developing new treatments for serious and debilitating diseases including rare genetic disorders. Led by industry professionals with extensive experience in all phases of drug development and asset acquisition, the company is currently advancing clinical stage investigational products to treat neuromuscular or CNS symptoms of rare diseases.

Pipeline

AMO Pharma's investigational drugs currently in development include:

- **AMO-01** for the treatment of Phelan-McDermid syndrome
- **AMO-02** for the treatment of congenital myotonic dystrophy
- **AMO-04** for the treatment of Rett syndrome



AMO Pharma's lead product candidate AMO-02 (tideglusib) is in development for the treatment of congenital myotonic dystrophy (CDM1), a rare genetic disease that is caused by a mutation in the DMPK gene. Symptoms typically begin at birth. As children with CDM1 age, the disease can affect many parts of the body, leading to significant cognitive and physical impairment.

The REACH CDM study is a global clinical trial evaluating the safety and efficacy of AMO-02 (tideglusib) for the treatment of CDM1 in children and adolescents. For more information on this trial and eligibility criteria, visit **reachcdm.com**.

REACH CDM

Dedication to Patients

As a foundation to our clinical development programs, we invite and work to build connections with leaders in patient advocacy to better understand the areas of unmet need and gain new insights related to the conditions we are targeting. These perspectives help us improve the quality of our research and identify opportunities to support important efforts in disease awareness and patient and clinician education. AMO Pharma's passion for drug development is strengthened and inspired by many personal connections to the rare disease community held by members of our senior team.

By understanding the patient experience, we are better able to advance drugs that will reduce disease burden and give patients the best chance for improved quality of life and health

Contact

London UK Office:
AMO Pharma, Ltd.
1 Park Row
Leeds LS1 5AB UK
Tel: +44 (0) 1483 319070

Durham US Office:
AMO Pharma, Ltd.
321 East Chapel Hill Street
3rd Floor
Durham, NC 27701 USA

For more information on the company, please email **info@amo-pharma.com**

If you are a patient or caregiver interested in matter(s) related to our pipeline or clinical trials, please email **Medinfo@amo-pharma.com**

Find us on **LinkedIn**

AMO PHARMA

www.amo-pharma.com

Management Team

Members of the AMO Pharma senior team have extensive experience in biomedical science and research with proven skill in all phases of drug development and commercialization. With bases in both the U.S. and the U.K., the company is able to leverage an international network of contacts and resources in all operational areas.

Ibraheem Mahmood, MD *Chief Executive Officer*

Ibraheem Mahmood has an extensive life science and finance background that spans more than 20 years. His experience includes previous roles in Lifescience M&A and Fundraising at Nomura, Lifescience Equity Research at Investec and Business Development and Corporate Venture Capital at Shire Pharmaceuticals. He served as President and CEO of the clinical operations services company DrugDev, which raised over $50m in financing and was acquired by IQVIA in 2017. Ibraheem studied medicine at the University of Oxford.

Michael Snape, PhD *Chief Scientific Officer*

Dr. Snape is a neurobiologist with extensive experience in the pharmaceutical industry, including leadership positions with large and emerging biopharmaceutical companies. He has founded and funded companies from inception through public offerings, and his principal experience is demonstrating clinical proof-of-concept with novel targeted therapeutics in rare diseases. He earned a PhD in neurobiology from London University and holds a faculty position at Case Western University.



Martyn Williams, MA, FCA *Chief Financial Officer*

Over the past 30 years Mr. Williams has held senior operational and financial management positions at several international businesses. Most recently he served as CEO of Ark Therapeutics plc. He has experience in international M&A transactions, including both acquisitions and divestments, as well as in strategic management of corporate growth and restructuring.

Joe Horrigan, MD *Chief Medical Officer*

Dr. Horrigan is a pediatric neuropsychiatrist. He was formerly Senior Director in the Neurosciences Medicines Development Center at GlaxoSmithKline and most recently served as Vice President of Clinical Development and Medical Affairs for Neuren Pharmaceuticals Limited. He received his undergraduate degree from Brown University and his medical degree from the University of Rochester.

Alison McMorn, PhD *Senior Vice President, Clinical Development*

Dr. McMorn is an experienced clinical development researcher and has led, planned and managed global clinical development programs for gastro-intestinal/hepatology, pain and psychiatry products. Most recently she served as a Director of Clinical Programs at Shire Pharmaceuticals. She holds an undergraduate degree in Pharmacology and a PhD in psychology from the University of Leeds, UK.

rev: 11 -FEB-2021